Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Batlevi · SciRah

Researcher profile · Semantic Scholar

C. Batlevi

Share profile

C. Batlevi — researcher profile on SciRah

h-index: 22
Works: 177
Citations: 2,232

Most-cited papers

Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
L. Budde, A. Olszewski, S. Assouline, I. Lossos +20 more
2023Nature Medicine102 citations Open access
Semantic Scholar
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
J. Soumerai, A. Mato, A. Dogan, V. Seshan +42 more
2021The Lancet Haematology85 citations Open access
Semantic Scholar
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
Robert N. Stuver, G. Shah, N. Korde, L. Roeker +29 more
2022Cancer Cell78 citations Open access
Semantic Scholar
Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study
Michael L. Wang, S. Assouline, M. Kamdar, N. Ghosh +12 more
2023Blood36 citations Open access
Semantic Scholar
A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma
Jae H. Park, C. Sauter, M. Palomba, G. Shah +12 more
2021Blood35 citations Open access
Semantic Scholar
Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
A. Olszewski, Herbert A. Eradat, A. Avigdor, N. Horowitz +23 more
2023Blood29 citations
Semantic Scholar
Modi ﬁ ed EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
M. Pennisi, Miriam Sánchez-Escamilla, Jessica R. Flynn, R. Shouval +22 more
202127 citations
Semantic Scholar
Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes
G. Salles, F. Morschhauser, L. Sehn, A. Herrera +21 more
2024Blood23 citations
Semantic Scholar
Taking the EZ Way: Targeting Enhancer of Zeste Homolog 2 in B-Cell Lymphomas
F. Morschhauser, G. Salles, C. Batlevi, H. Tilly +4 more
2022Blood reviews20 citations Open access
Semantic Scholar
Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study
D. Qualls, Michael J. Buege, Phuong H. Dao, P. Caimi +14 more
2022Blood19 citations Open access
Semantic Scholar
Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
Caitlin M. Stewart, L. Michaud, Karissa A. Whiting, Reiko Nakajima +20 more
2021Clinical Cancer Research19 citations Open access
Semantic Scholar
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study
M. Maris, G. Salles, W. Kim, Tae Min Kim +16 more
2024Targeted oncology14 citations Open access
Semantic Scholar
Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)
Anita Kumar, J. Soumerai, J. Abramson, C. Batlevi +20 more
2021Blood13 citations Open access
Semantic Scholar
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study
Bei Hu, P. Reagan, L. Sehn, Jeff P. Sharman +15 more
2025Blood Advances12 citations Open access
Semantic Scholar
A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
J. Chavez, A. Olszewski, M. Bastos-Oreiro, S. Assouline +18 more
2024Blood11 citations
Semantic Scholar
Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study
Ana Alarcon Tomas, J. Fein, S. Fried, Warren Fingrut +26 more
2021Blood11 citations Open access
Semantic Scholar
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting
Serena Zheng, K. Gupta, P. Goyal, Reiko Nakajima +19 more
2023Cancers10 citations Open access
Semantic Scholar
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma
Karthik D. Nath, A. A. Tomas, J. Flynn, J. Fein +21 more
2022Transplantation and Cellular Therapy9 citations Open access
Semantic Scholar
MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN IS SUPERIOR TO R‐GemOx IN TRANSPLANT‐INELIGIBLE PATIENTS WITH R/R LBCL: PRIMARY RESULTS OF THE PHASE III SUNMO TRIAL
J. Westin, H. Zhang, W. Kim, L. Fogliatto +17 more
2025Hematological Oncology8 citations
Semantic Scholar
Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
C. Batlevi, G. Salles, Steven I. Park, T. Phillips +12 more
2022Blood8 citations Open access
Semantic Scholar
Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
C. Batlevi, Steven I. Park, L. Nastoupil, T. Phillips +11 more
2021Blood8 citations Open access
Semantic Scholar
THE BENEFIT OF POLA‐R‐CHP IN DLBclass‐DEFINED MOLECULAR SUBSETS OF NEWLY DIAGNOSED DLBCL IN THE POLARIX TRIAL
E. Calabretta, K. Lu, X. Zhao, C. Stewart +15 more
2025Hematological Oncology6 citations
Semantic Scholar
Pola-R-CHP or R-CHOEP for first-line therapy of younger patients with high-risk diffuse large B-cell lymphoma: a retrospective comparison of two randomized phase 3 trials
Georg Lenz, Hervé Tilly, M. Ziepert, B. Altmann +11 more
2024Leukemia6 citations Open access
Semantic Scholar
Retrospective characterization of nodal marginal zone lymphoma
Robert N. Stuver, E. Drill, D. Qualls, M. Okwali +25 more
2023Blood Advances6 citations Open access
Semantic Scholar
SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
J. Westin, A. Olszewski, L. Fogliatto, W. Kim +13 more
2023Journal of Clinical Oncology6 citations
Semantic Scholar
Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
M. Shadman, A. Mato, C. Batlevi, I. Flinn +18 more
2022Blood6 citations Open access
Semantic Scholar
Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
Robert N. Stuver, L. Michaud, C. Casulo, R. Advani +27 more
2022Blood6 citations Open access
Semantic Scholar
Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study
L. Budde, M. Kamdar, S. Assouline, Julio C. Chavez +19 more
2026Blood5 citations Open access
Semantic Scholar
POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA‐R‐GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PHASE III POLARGO TRIAL
J. Sancho, Z. Li, T. Vassilakopoulos, A. Viardot +15 more
2025Hematological Oncology5 citations
Semantic Scholar
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
Z. Epstein-Peterson, E. Drill, U. Aypar, C. Batlevi +20 more
2023Haematologica5 citations Open access
Semantic Scholar
Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)
D. Sermer, Santosha A. Vardhana, E. Biggar, A. Moskowitz +22 more
2021Blood4 citations Open access
Semantic Scholar
Outcomes of tafasitamab and lenalidomide in large B‐cell lymphoma based on prior CD19‐directed CAR T exposure
Mwanasha H. Merrill, R. Redd, Nicholas Lambert, P. Caimi +21 more
2025HemaSphere3 citations
Semantic Scholar
FIXED‐DURATION OUTPATIENT SUBCUTANEOUS MOSUNETUZUMAB + POLATUZUMAB VEDOTIN SHOWS ROBUST EFFICACY IN A PHASE II STUDY OF RELAPSED/REFRACTORY POST‐BTKi MANTLE CELL LYMPHOMA
L. Budde, M. Kamdar, S. Assouline, N. Ghosh +16 more
2025Hematological Oncology3 citations
Semantic Scholar
MCL-1493: Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL)
Michael L. Wang, M. Kamdar, S. Assouline, Nilanjan Ghosh +16 more
2025Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).
S. Assouline, L. Budde, J. Chavez, C. Diefenbach +15 more
2024Journal of Clinical Oncology3 citations Open access
Semantic Scholar
TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma
R. Shouval, Ana Alarcon Tomas, J. Fein, J. Flynn +20 more
2021Blood3 citations
Semantic Scholar
Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
Z. Epstein-Peterson, E. Drill, U. Aypar, C. Batlevi +20 more
2024Haematologica2 citations Open access
Semantic Scholar
Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma
D. Qualls, Nicholas Lambert, P. Caimi, Mwanasha H. Merrill +20 more
2023Blood2 citations Open access
Semantic Scholar
Severe Persistent Cytopenias Following CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
Magdalena Corona de Lapuerta, R. Shouval, Ana Alarcon Tomas, J. Flynn +14 more
2022Transplantation and Cellular Therapy2 citations Open access
Semantic Scholar
Five-Year Experience Using Bridging Radiotherapy Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapies for B-Cell Malignancies at Memorial Sloan Kettering Cancer Center
E. Silverman, H. Hubbeling, M. Palomba, N. Wijetunga +17 more
2021Blood2 citations Open access
Semantic Scholar
Novel targeted agents for follicular lymphoma
C. Batlevi, F. Morschhauser
20212 citations Open access
Semantic Scholar
Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patie
W. Kim, J. Westin, D. Maruyama, Hui-Lai Zhang +16 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma
Julio C. Chavez, M. Bastos-Oreiro, C. Diefenbach, I. Lossos +14 more
2026American journal of hematology/oncology1 citations Open access
Semantic Scholar
Multivariable analyses (MVAs) of overall survival (OS) in the phase 3 SUNMO, STARGLO, and POLARGO trials in relapsed/refractory large B-cell lymphoma (LBCL).
M. Matasar, J. Westin, J. Abramson, A. Olszewski +10 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration
Lei Gao, A. Kallam, G. Shouse, John H. Baird +18 more
2025Blood Advances1 citations
Semantic Scholar
Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study
M. Kamdar, Julio Chavez, A. Olszewski, S. Assouline +15 more
2025Blood1 citations
Semantic Scholar
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma
E. Joffe, Manik Uppal, Serena Zheng, K. Bantilan +22 more
2025Haematologica1 citations Open access
Semantic Scholar
Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities
James K. Godfrey, Sravya Tumuluru, Alan Cooper, G. Salles +11 more
2025Blood1 citations
Semantic Scholar
Rituximab +/- Ibrutinib As First Line Therapy for Marginal Zone Lymphoma
A. Noy, W. Thet, Shreya Vemuri, V. Seshan +12 more
2024Blood1 citations
Semantic Scholar
Deep Learning Predicts Risk of Large B-Cell Lymphoma Progression upon R-CHOP Therapy from Baseline Histology
Samaneh Abbasi Sureshjani, Anil Yüce, C. Doerig, Agata Mosinska +5 more
2024Blood1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Palomba×15
Invite
M. Palomba — researcher profile on SciRah
L. Budde×13
Invite
L. Budde — researcher profile on SciRah
S. Pham×12
Invite
S. Pham — researcher profile on SciRah
M. Matasar×12
Invite
M. Matasar — researcher profile on SciRah

×12

Invite

A. Zelenetz — researcher profile on SciRah

Invite

I. To — researcher profile on SciRah

Anita Kumar×10

Invite

Anita Kumar — researcher profile on SciRah

Invite

S. Naik — researcher profile on SciRah

Invite

W. Ead — researcher profile on SciRah

A. Olszewski×8

Invite

A. Olszewski — researcher profile on SciRah

Invite

A. Noy — researcher profile on SciRah

Invite

G. Shah — researcher profile on SciRah